CPRX vs. ZTS: Which Stock Is the Better Value Option?

Core Viewpoint - Catalyst Pharmaceutical (CPRX) is currently more attractive to value investors compared to Zoetis (ZTS) based on various valuation metrics and earnings outlook improvements [3][7]. Valuation Metrics - CPRX has a forward P/E ratio of 9.50, significantly lower than ZTS's forward P/E of 19.12 [5]. - The PEG ratio for CPRX is 0.80, indicating a more favorable valuation relative to its expected earnings growth, while ZTS has a PEG ratio of 2.11 [5]. - CPRX's P/B ratio stands at 3.03, compared to ZTS's P/B of 9.95, further highlighting the relative undervaluation of CPRX [6]. Earnings Outlook - CPRX has experienced stronger estimate revision activity, suggesting a more positive earnings outlook compared to ZTS [3][7]. - The Zacks Rank for CPRX is 2 (Buy), indicating a favorable investment position, while ZTS has a Zacks Rank of 4 (Sell) [3].